BioNTech : Second Quarter 2023 Earnings Presentation

2nd Quarter 2023

Financial Results & Corporate Update

August 7, 2023

This Slide Presentation Includes Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech's expected revenues and net profit related to sales of BioNTech's COVID-19 vaccine, referred to as COMIRNATY® where approved for use under full or conditional marketing authorization, in territories controlled by BioNTech's collaboration partners, particularly for those figures that are derived from preliminary estimates provided by BioNTech's partners; the rate and degree of market acceptance of BioNTech's COVID-19 vaccine and, if approved, BioNTech's investigational medicines; expectations regarding anticipated changes in COVID-19 vaccine demand, including changes to the ordering environment and expected regulatory recommendations to adapt vaccines to address new variants or sublineages; the initiation, timing, progress, results, and cost of BioNTech's research and development programs, including those relating to additional formulations of BioNTech's COVID-19 vaccine, and BioNTech's current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work and the availability of results; our expectations with respect to our intellectual property; the impact of the Company's acquisition of InstaDeep Ltd. and collaboration and licensing agreements with OncoC4, Inc., Duality Biologics (Suzhou) Co. Ltd and others; the development of sustainable vaccine production and supply solutions and the nature and feasibility of these solutions; and BioNTech's estimates of commercial and other revenues, cost of sales, research and development expenses, sales and marketing expenses, general and administrative expenses, capital expenditures, income taxes, net profit, cash, cash equivalents and security investments, shares outstanding and cash outflows and share consideration. In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech's control, and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: BioNTech's pricing and coverage negotiations with governmental authorities, private health insurers and other third-party payors after BioNTech's initial sales to national governments; the future commercial demand and medical need for initial or booster doses of a COVID-19 vaccine; competition from other COVID-19 vaccines or related to BioNTech's other product candidates, including those with different mechanisms of action and different manufacturing and distribution constraints, on the basis of, among other things, efficacy, cost, convenience of storage and distribution, breadth of approved use, side-effect profile and durability of immune response; the timing of and BioNTech's ability to obtain and maintain regulatory approval for BioNTech's product candidates; the ability of BioNTech's COVID-19 vaccines to prevent COVID-19 caused by emerging virus variants; BioNTech's and its counterparties' ability to manage and source necessary energy resources; BioNTech's ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of BioNTech's third-party collaborators to continue research and development activities relating to BioNTech's development candidates and investigational medicines; the impact of the COVID-19 pandemic on BioNTech's development programs, supply chain, collaborators and financial performance; unforeseen safety issues and claims for potential personal injury or death arising from the use of BioNTech's COVID-19 vaccine and other products and product candidates developed or manufactured by BioNTech; BioNTech's and its collaborators' ability to commercialize and market BioNTech's COVID-19 vaccine and, if approved, its product candidates; BioNTech's ability to manage its development and expansion; regulatory developments in the United States and other countries; BioNTech's ability to effectively scale BioNTech's production capabilities and manufacture BioNTech's products, including BioNTech's target COVID-19 vaccine production levels, and BioNTech's product candidates; risks relating to the global financial system and markets; and other factors not known to BioNTech at this time. You should review the risks and uncertainties described under the heading "Risk Factors" in BioNTech's Report on Form 6-K for the period ended June 30, 2023 and in subsequent filings made by BioNTech with the SEC, which are available on the SEC's website at https://www.sec.gov/. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this presentation in the event of new information, future developments or otherwise. These forward-looking statements are based on BioNTech's current expectations and speak only as of the date hereof.

2

1

2

3

4

2nd Quarter 2023 Highlights

Ugur Sahin, Chief Executive Officer

COVID-19 & Pipeline Update

Özlem Türeci, Chief Medical Officer

Financial Results

Jens Holstein, Chief Financial Officer

Strategic Outlook

Ryan Richardson, Chief Strategy Officer

1 2nd Quarter 2023 Highlights

Ugur Sahin, Chief Executive Officer

2023 Strategic Priorities and Achievements in Q2 2023

COVID-19 franchise1

2023 Strategic Priorities

Sustain leadership in COVID-19 vaccines Advance next-gen vaccines

Q2 Achievements

Prepare launch activities for variant-adapted vaccine

Submitted application to EU and U.S. regulators for variant- adapted COVID-19 vaccine

Initiated development & manufacturing of COVID-19 vaccines better matched to currently circulating sublineages for 2023/2024 season

Immuno-oncology

Advance platforms for solid tumors

Initiate multiple trials with registrational potential

	Two new	DualityBio
	collaborations	ADCs - A promising combination
		backbone to our pipeline
		OncoC4
		A differentiated anti CTLA-4
		antibody program
	Three clinical	BNT211
	data updates	BNT316/ONC-392 (gotistobart)2
	at ASCO
	BNT323/DB-13033
	Phase 3	BNT316/ONC-392
	Trial Start
	(gotistobart)2

Infectious diseases

Initiate and accelerate clinical programs for high medical need indications

Trial Start

Tuberculosis4

BNT164

Multiple data updates expected in 2H 2023

HSV5	Malaria
BNT163	BNT165

1. Partnered with Pfizer; 2. Partnered with OncoC4; 3. Partnered with DualityBio; 4. In collaboration with Bill & Melinda Gates Foundation; 5. Collaboration with University of Pennsylvania. HSV = Herpes simplex virus; ADC = antibody-drug conjugate; CTLA = cytotoxic T-lymphocyte-associated protein.

5